Brexit: The View For Pharma In 2021 And Beyond
With the end of the Brexit transition period fast approaching, life sciences companies need to be ready for some major changes to drug regulations as well as the impact of new border and customs controls on the flow of medicines between Great Britain, Northern Ireland and the EU. In Vivo looks at what is at stake, and what still needs to be done, as the UK prepares to leave the EU single market and customs union at the beginning of 2021.
You may also be interested in...
In its latest letter to medicines and medical product companies, the UK's Department of Health and Social Care says the biggest potential cause of disruption to supplies could be failure to prepare for border controls implemented by the EU member states after the end of the Brexit transition period.
In another of the many guidances it has issued on medicines regulation in the post-Brexit UK, the MHRA explains the additional information it will need from companies whose EU marketing authorizations are converted into national MAs in January 2021, and the new labeling requirements for those products.
A project is about to begin to understand the factors that influence marketing decisions in the various EU member states.